Jenga Biosciences develops and commercializes advanced oncology treatments specifically for companion animals suffering from cancer. The company manages the complex process from identifying promising research to navigating clinical trials, regulatory approval, and manufacturing. This focus ensures effective veterinary cancer therapies reach pets quickly to extend and improve their quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Canine oral melanoma and other solid tumors present significant challenges in veterinary oncology, often leading to poor health outcomes and reduced quality of life for affected animals. Current treatment options may be limited in efficacy or accessibility, leaving a critical need for more targeted and effective therapies.
Solution
Jenga Biosciences focuses on developing and commercializing targeted therapies to address canine oral melanoma and other solid tumors. By identifying promising research breakthroughs in veterinary oncology, the company navigates the complexities of research protocols, clinical trials, regulatory pathways, manufacturing, and commercialization to bring effective treatments to market. Jenga Biosciences aims to provide veterinarians with advanced cancer treatment options that extend and enhance the lives of pets, offering families more time with their beloved companions.
Target Audience
The primary customers are veterinarians specializing in oncology and animal hospitals seeking advanced cancer treatment options for canine patients.
Features
- Focus on targeted therapies for canine oral melanoma and other solid tumors.
- Identification and development of promising research breakthroughs in veterinary oncology.
- Expertise in navigating research protocols, clinical trials, and regulatory pathways.
- Streamlined manufacturing processes to ensure treatment availability.
- Commercialization strategies to make effective treatments accessible to veterinarians.